Drug Details
| General Information of the Drug (ID: DR2806) | ||||
|---|---|---|---|---|
| Name |
Bacillus Calmette-Guerin
|
|||
| Synonyms |
Bromocresol green; 76-60-8; BROMCRESOL GREEN; bromo cresol green; 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; Tetrabromo-m-cresolphthalein sulfone; 3',3'',5',5''-Tetrabromo-m-cresolsulfonephthalein; Bromocresol blue; NSC 7817; UNII-8YGN0Y942M; EINECS 200-972-8; BRN 0372527; CHEMBL145704; 8YGN0Y942M; Bromocresol Green, ACS reagent; NSC7817; FRPHFZCDPYBUAU-UHFFFAOYSA-N; MFCD00005874; o-Toluenesulfonic acid, alpha-hydroxy-, gamma-sultone; BROMOCRESOL GREEN, ACS; Phenol, 4,4'-(3H-2,1-benzox
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Bladder cancer [ICD-11: 2C94] | Phase 3 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C21H14Br4O5S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br
|
|||
| InChI |
1S/C21H14Br4O5S/c1-9-12(7-14(22)19(26)17(9)24)21(13-8-15(23)20(27)18(25)10(13)2)11-5-3-4-6-16(11)31(28,29)30-21/h3-8,26-27H,1-2H3
|
|||
| InChIKey |
FRPHFZCDPYBUAU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 76-60-8
|
|||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CD83 | Molecule Info | ||
| Up-regulation | Expression | FUN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | IER3 | Molecule Info | |||
| Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | ||
| In-vivo Model | 0.15 mL human bladder cancer cell suspension (with a concentration of 1 * 107 /ml) was injected through the catheter into the urinary bladder cavity. | |||||
| Experimental
Result(s) |
Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MBT-2 | CVCL_4660 | Bladder transitional cell carcinoma | Mus musculus | ||
| 253J-BV | CVCL_7937 | Bladder carcinoma | Homo sapiens | |||
| KU-7 | CVCL_4714 | Bladder cancer | Homo sapiens | |||
| RT4v6 | CVCL_T027 | Bladder carcinoma | Homo sapiens | |||
| In-vivo Model | Animal models were constructed by subcutaneously injecting MBT-2 cells into both flanks of C3H female mice. | |||||
| Experimental
Result(s) |
Curcumin potentiates the antitumor effect of BCG through the inhibition of NF-kappaB and induction of TRAIL receptors in bladder cancer cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Prostaglandin transporter (SLC21A2) | Molecule Info | [4] | |
